Event Title

P-22 Synthesis and Anticancer Activity of Potential Hybrid Aspirin Drugs

Presenter Information

Frentzen Pakpahan

Start Date

2-28-2020 2:30 PM

Description

Aspirin acts primarily as an anti-inflammatory drug, but recent research has demonstrated a side effect of reducing the risk for certain types of cancer, notably colorectal cancer. Modification of aspirin’s chemical structure to include other drugs may increase aspirin’s anticancer potency. A novel synthesis of a halogenated aspirin acylal via electrophilic carbonyl addition has been tested and found successful using NMR and IR testing. It is further hypothesized that the modified hybrid aspirin would increase its native potency against cancer. Both aspirin and the hybrid will be tested on glioblastoma cells grown in vitro to determine their anticancer potency.

Acknowledgments

J.N. Andrews Honors Scholar

Mentors: Desmond H. Murray, Chemistry & Biochemistry; Denise Smith, Biology

This document is currently not available here.

Share

COinS
 
Feb 28th, 2:30 PM

P-22 Synthesis and Anticancer Activity of Potential Hybrid Aspirin Drugs

Aspirin acts primarily as an anti-inflammatory drug, but recent research has demonstrated a side effect of reducing the risk for certain types of cancer, notably colorectal cancer. Modification of aspirin’s chemical structure to include other drugs may increase aspirin’s anticancer potency. A novel synthesis of a halogenated aspirin acylal via electrophilic carbonyl addition has been tested and found successful using NMR and IR testing. It is further hypothesized that the modified hybrid aspirin would increase its native potency against cancer. Both aspirin and the hybrid will be tested on glioblastoma cells grown in vitro to determine their anticancer potency.